Stämpfli, Dominik http://orcid.org/0000-0001-5293-134X
Weiler, Stefan http://orcid.org/0000-0003-1087-7597
Weiniger, Carolyn F. http://orcid.org/0000-0001-5049-1504
Burden, Andrea M. http://orcid.org/0000-0001-7082-8530
Heesen, Michael http://orcid.org/0000-0002-6528-8100
Funding for this research was provided by:
Swiss Federal Institute of Technology
Article History
Received: 7 July 2020
Accepted: 2 December 2020
First Online: 19 December 2020
Compliance with ethical standards
:
: The authors declare that they have no conflicts of interest relevant to the content of this study. SW is a member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. The authors declare that they performed their research in compliance with the caveat document “Statement of reservations, limitations and conditions relating to data released from VigiBase, the WHO global database of individual case safety reports (ICSRs)” by the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, published 2018-11-20 on ExternalRef removed.
: This was an observational study with anonymous pharmacovigilance data.
: Not applicable.
: Not applicable.
: The unformatted code used during the current study is available from the corresponding author on reasonable request.